A higher percentage of patients treated with an experimental Pfizer Inc drug for osteoporosis died during a clinical trial compared with a placebo, U.S. drug reviewers said in an analysis released on Thursday.

The higher proportion of deaths through five years was statistically significant only for the lowest dose of the drug called Fablyn, said Food and Drug Administration reviewers. More patients given Fablyn, which was co-developed with Ligand Pharmaceuticals Inc, also developed blood clots.

More...